AVANIR Pharmaceuticals (AVNR)
$1.74
-0.04 (-2.25%)
| CAPS Rating |
|
|---|---|
| Open | $1.76 |
| Previous Close | $1.78 |
| Daily Range | $1.74 - $1.80 |
| 52-Week Range | $0.23 - $4.09 |
| Market Cap | $136.52M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 203,358 |
| Average Daily Volume | 961,000 |
AVNR
VS S&P 500 (SPY)
How do you think AVNR will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
AVNR Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
AVNR News and Commentary
- CORRECT(11/10): Neurological Drug Meets Goal In Extended Trial – SmartMoney
- UPDATE 1-Avanir posts positive Zenvia data, shares rise – Reuters
- UPDATE 1-Avanir drug shows promise for MS-related pain – Reuters
- UPDATE 1-Avanir to get new patent for neurological disorder drug – Reuters
- VaxGen, Inc. (Public, OTC:VXGN Pervention is better than cure – Blog at The Motley Fool
- 9 Stocks to Shake the Market – The Motley Fool
Related News and Articles
- A Mostly Meaningless FDA Approval – The Motley Fool
- Biotech Bargains for Your Portfolio – The Motley Fool
- 7 of the Most Efficient Companies on the Planet – The Motley Fool
- 5-Star Stocks Poised to Pop: Diageo – The Motley Fool
- 3 China Profit Plays – The Motley Fool
- A Big Upgrade for Amylin Pharmaceuticals – The Motley Fool
- Build Your Fortune With These Winners – The Motley Fool
- Still Enjoying Those Acquisitions, Pfizer? – The Motley Fool
- Novartis Didn't Know JAK, Until Now – The Motley Fool
- 12 Companies With Ironclad Balance Sheets – The Motley Fool
- 7 Dividend Divas – The Motley Fool
- A Schizophrenic Move by Merck? – The Motley Fool
RSS Headlines
Fool UK
